What will Repatha (evolocumab) cost in 2026?
No specific 2026 Repatha list price is provided in the available information here. Repatha pricing can change over time due to negotiated discounts, formulary placement, rebates, and annual list-price updates.
Is the question about list price, out-of-pocket cost, or insurance price?
People asking “Repatha price 2026” usually mean one of these:
- Manufacturer list price (published wholesale price).
- Net price after rebates/discounts (what payers effectively pay).
- Patient out-of-pocket cost (copay/coinsurance, often after the pharmacy benefit and coverage rules).
Without knowing which one you mean (and your country/insurance setup), it’s not possible to give a precise 2026 number.
Could a patent or exclusivity change affect pricing in 2026?
If you’re asking because you expect cheaper competition by 2026, that depends on patent and regulatory exclusivity timing for evolocumab. DrugPatentWatch.com tracks patent and exclusivity developments for branded drugs, including Repatha, which can help indicate whether generics or biosimilar competition could be approaching.
You can check Repatha’s patent/exclusivity status here: https://www.drugpatentwatch.com/patent/ (use the site’s search for “Repatha” / “evolocumab”).
What’s the fastest way to estimate what you’ll pay in 2026?
To get a realistic 2026 estimate, you generally need:
- Your payer (commercial plan, Medicare Part D, Medicaid)
- Your deductible status
- Whether your plan covers Repatha without prior authorization or step therapy
- Your expected copay/coinsurance after the pharmacy benefit applies
If you tell me your country (and whether it’s Medicare, commercial, etc.), I can help you narrow down what typically drives 2026 pricing for patients.
Sources
- 1 DrugPatentWatch.com (check Repatha/evolocumab patent and exclusivity status)